SCHEMBL2118676

SCHEMBL2118676

CCCCCCCCCCCCCCC(=O)C(=O)NC(C(=O)N[C@@H](C)C(=O)O)C(C)C

nearest known ligand 0.76

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 6/20 0.76
PLA2G5 P39877 3/20 0.76
FAAH O00519 5/20 0.49
PLA2G4A P47712 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
CES2 O00748 4/20 0.42
CES1 P23141 4/20 0.42
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
SLC6A5 Q9Y345 1/20 0.41
MME P08473 1/20 0.39
ACE P12821 1/20 0.39
CPA1 P15085 1/20 0.39
ACE2 Q9BYF1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118667 1.00 PLA2G2A (0.76) PLA2G2APLA2G5FAAHPLA2G4ASMN1; SMN2
SCHEMBL30798618 0.86 PLA2G2A (1.00) PLA2G2APLA2G5FAAHPLA2G4ASMN1; SMN2
SCHEMBL29948915 0.86 PLA2G2A (1.00) PLA2G2APLA2G5FAAHPLA2G4ASMN1; SMN2
SCHEMBL30018617 0.85 FAAH (0.62) PLA2G2APLA2G5FAAHSMN1; SMN2MEN1
SCHEMBL30018188 0.85 FAAH (0.62) PLA2G2APLA2G5FAAHSMN1; SMN2MEN1
SCHEMBL2119435 0.85 PLA2G2A (0.70) PLA2G2APLA2G5FAAHPLA2G4ASMN1; SMN2
SCHEMBL2119429 0.85 PLA2G2A (0.70) PLA2G2APLA2G5FAAHPLA2G4ASMN1; SMN2
SCHEMBL30076306 0.84 FAAH (0.60) PLA2G2APLA2G5FAAHSMN1; SMN2MEN1
SCHEMBL2120792 0.82 PLA2G2A (0.69) PLA2G2APLA2G5FAAHPLA2G4ASMN1; SMN2
SCHEMBL2120784 0.82 PLA2G2A (0.69) PLA2G2APLA2G5FAAHPLA2G4ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580852-B2 2-oxamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudopeptides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-11-12 US disclosed
US-20120095096-A1 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-04-19 US disclosed
WO-2010123832-A2 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095096-A1 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES PLA2G2E, PLA2G4A, PLAA PLA2G2A 6/4885PLA2G5 16/4885FAAH 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.